Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Diakonos Oncology Corporation
Pheast Therapeutics
Eli Lilly and Company
InSightec
Servier
Philogen S.p.A.
Novartis
Nested Therapeutics, Inc
Eli Lilly and Company
InSightec
Eli Lilly and Company
InSightec
InSightec
Jazz Pharmaceuticals
SonoClear AS
Telix Pharmaceuticals (Innovations) Pty Limited
AstraZeneca
Jazz Pharmaceuticals
CNS Pharmaceuticals, Inc.
Tango Therapeutics, Inc.
EMD Serono
Myosin Therapeutics Inc.
Black Diamond Therapeutics, Inc.
Novartis
Merck Sharp & Dohme LLC
NaviFUS Corporation
Novelwise Pharmaceutical Corporation
Iambic Therapeutics, Inc
Merck Sharp & Dohme LLC
Tango Therapeutics, Inc.
Beijing Biotech
NaviFUS Corporation
Parabilis Medicines, Inc.
NaviFUS Corporation
NaviFUS Corporation
SpringWorks Therapeutics, Inc.
Hoffmann-La Roche
Stemline Therapeutics, Inc.
Akouos, Inc.
Alpha Tau Medical LTD.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Akouos, Inc.
Actuate Therapeutics Inc.
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Fore Biotherapeutics
Jecho Biopharmaceuticals Co., Ltd.
Novartis
Amgen
Aesculap AG